CN1120832A - 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 - Google Patents

涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 Download PDF

Info

Publication number
CN1120832A
CN1120832A CN94191734A CN94191734A CN1120832A CN 1120832 A CN1120832 A CN 1120832A CN 94191734 A CN94191734 A CN 94191734A CN 94191734 A CN94191734 A CN 94191734A CN 1120832 A CN1120832 A CN 1120832A
Authority
CN
China
Prior art keywords
coating
spc
sodium percarbonate
peroxide
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94191734A
Other languages
English (en)
Inventor
B·伯奇-弗兰克
C-J·克拉森
T·莱瑟
K·米勒
M·贝沃斯多夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Publication of CN1120832A publication Critical patent/CN1120832A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B15/00Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
    • C01B15/055Peroxyhydrates; Peroxyacids or salts thereof
    • C01B15/10Peroxyhydrates; Peroxyacids or salts thereof containing carbon
    • C01B15/106Stabilisation of the solid compounds, subsequent to the preparation or to the crystallisation, by additives or by coating
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B15/00Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
    • C01B15/055Peroxyhydrates; Peroxyacids or salts thereof
    • C01B15/10Peroxyhydrates; Peroxyacids or salts thereof containing carbon
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0039Coated compositions or coated components in the compositions, (micro)capsules
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/39Organic or inorganic per-compounds
    • C11D3/3942Inorganic per-compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Detergent Compositions (AREA)

Abstract

过碳酸钠通常以涂敷颗粒形式使用,以增加其在洗涤剂中的贮存稳定性。根据本发明涂敷的过碳酸钠颗粒的涂层含有四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的产物。涂敷过碳酸钠颗粒通过将上述反应产物的溶液涂敷到过碳酸盐颗粒上来制备。含有根据本发明涂敷的过碳酸钠颗粒的洗涤剂、漂白剂和清洁剂组合物具有很高的贮存稳定性。

Description

涂敷过碳酸钠颗粒及其生产方法和 含此颗粒的洗涤剂、清洁剂及漂白剂组合物
本发明涉及涂敷的过碳酸钠颗粒,其涂层含过氧化的硼化合物,它赋予过碳酸钠高的贮存稳定性。本发明也涉及生产该涂敷的过碳酸钠颗粒的方法,通过将一种或多种涂层组分,尤其以其水溶液形式涂敷到待涂敷的过碳酸钠上及涂敷到含有根据本发明的涂敷的过碳酸钠颗粒的洗涤剂、清洁剂及漂白剂组合物中。
过碳酸钠(2Na2CO3.3H2O2)在洗涤剂、漂白剂及清洁制剂中用做活性氧组分。考虑到过碳酸钠在潮湿环境中及在洗涤剂、清洁制剂中各种组分的存在下的贮藏稳定性差,必须提高过碳酸钠的稳定性以减少活性氧(Oa)的损失。稳定化的主要方法是将过碳酸钠颗粒涂敷上一层稳定组分。如已有的将过碳酸钠涂敷上石蜡或聚乙二醇。但遗憾的是,这种方法不仅使其在水中的溶解度大大降低,而且也不能获得足够长期的稳定性。即使碱金属硅酸盐涂敷到过碳酸钠的颗粒上,正如DE—OS 2652776中建议的,也不能达到足够的稳定性,另外还引入了不需要的不溶性组分。在DE—OS2417572和DE—OS 2622610所述的方法中,用硫酸钠和碳酸钠或硫酸钠、碳酸钠和硅酸钠做涂层组分。在这些方法中,将涂层组分的溶液喷洒在流化床干燥塔中的过碳酸钠颗粒上。获得足够的稳定性需要大量的涂敷物,从而相应使活性氧含量大大降低。
尽管从DE—PS 2800 916中了解到,含有偏硼酸、原硼酸和四硼酸中至少一种硼化合物的涂敷物能用于稳定过碳酸钠,但是,正如比较实施例中所示的DE—OS 3321082中把用这种方法获得的稳定效果看成是不够。然而,具有含硼酸钠的壳层的过碳酸钠被认为是有有利的。但是,正如本申请书的发明人在重复DE—OS33 21082的实施例时所发现的,为了获得足够的稳定性,硼酸盐及非必须的其它涂敷物组分不得不大量地存在于涂层中,以致使得以稳定的过碳酸钠的有效活性氧含量总是低于14wt%。在EP—A 0487256中进一步发展了使用硼酸盐的稳定化方法,尽管这里公开的涂敷方法至少包括两步,所以在技术上是复杂的。
最后,DE—AS 2458326中描述了一种稳定过碳酸钠的方法,即使是它与清洁剂掺和的情况下该方法也能提高纯过碳酸钠的贮存稳定性。在该法中,用加有过硼酸钠粉末的憎水有机化合物液涂敷过碳酸钠。该方法的弊端在于:为使工艺易于操作,作用的这种憎水液态有机化合物需要用低级醇稀释。另外,涂敷化合物的使用量十分高,即按过碳酸钠计5~20wt%的过硼酸钠和5~10wt%的憎水有机化合物。
DE—PS 2651442中介绍的涂敷过碳酸钠颗粒由过碳酸钠核及通式为NaBO2·H2O2·nH2O的过硼酸钠涂层构成,其中n小于3。按照DE—PS 2712139,涂层还可以含硅酸钠和其它加水粘合的物质。为了生产上述涂敷过碳酸钠颗粒,首先将过碳酸钠用水或硅酸钠水溶液湿润,水或溶液的用量极少以使过硼酸钠不至于转化成四水化合物,随后将湿润的过碳酸钠涂敷上一层无水过硼酸钠。DE—PS 2810379中介绍了上述方法的进一步改进,其中包括将过硼酸钠水溶液和硅酸钠溶液在40~60℃下喷洒在过碳酸钠上,其中过硼酸钠水溶液浓度为每升溶液中含50~500g四水过硼酸钠,然后全部或部分地除去过碳酸钠颗粒上引入的水份。
如迄今未出版的德国专利申请P 4306399.3中公开的,上述方法可以相当程度地得到简化,即在固/液分离器中部分分离湿法生产过碳酸钠产生的母液后,用过硼酸钠(NaBO2·H2O2)溶液冲洗上述湿法生产的过碳酸钠。尽管所需的涂敷物量很少,但在过碳酸钠的贮存中可以获得高的活性氧稳定性,这种过碳酸钠与典型的含沸石的洗涤剂塔粉混和。
含一水或四水过硼酸盐的涂敷物优于含硼酸盐或硼酸的过碳酸钠涂敷物,前者几乎不影响过碳酸钠颗粒中活性氧含量。
本发明论述的问题是使用新型含过氧的硼化合物进一步提高过碳酸钠的稳定性,并且提供了新型的涂敷的过碳酸钠颗粒,在相同的硼含量下,该颗粒比已知的有过硼酸盐涂层的过碳酸钠颗粒,在与洗涤剂组份混合贮存时,具有更高的活性氧稳定性。
因此,本发明涉及一种涂敷的过碳酸钠颗粒,它包含核和涂层,其核基本上为过碳酸钠,涂层至少含一种含过氧的硼化合物,其特征在于,从四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应得到的一种或多种反应产物用做含过氧的硼化合物。
涂敷颗粒的核基本上由过碳酸钠组成。“基本上”意味着过碳酸钠中还可能含有生产过程中加入的其它组成,例如苏打和少量的氯化钠以及结晶抑制剂,如偏磷酸盐或多羧酸以及常用的稳定剂,如镁盐和硅酸钠。术语“基本上”也意指过碳酸钠已经具有稳定组分涂层,例如膦酸盐、磷酸盐、苏打、水玻璃、镁盐、氨基羧酸盐和氨基膦酸盐以及羟基羧酸盐(hydroxycarboxylates)聚合物中任一种。一般来讲,已提出的任何涂敷组分甚至都可以是常见的硼化合物,尽管在要生产低硼含量的、涂敷的过碳酸钠颗粒的场合下,这看来是不适当的。
本发明方法中使用的过碳酸钠已经可以用标准方法生产。标准生产方法尤其包括所谓的湿法,其中苏打和过氧x氢在水相中发生反应,随后过碳酸钠结晶;以及所谓的喷淋法,其中含苏打及过氧化氢的水溶液喷淋到流化床干燥塔中的过碳酸钠颗粒上;还有所谓的干法,其中过氧化氢浓溶液与无水苏打反应。如果需要,标准生产方法之后还有标准涂敷方法。
按照本发明,涂敷的过碳酸钠颗粒中起稳定作用的壳层内含过氧化物的反应产物,该产物来源于四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液的反应,并且在与涂敷过碳酸钠颗粒相应的标准干燥条件下部分或全部地除去了水份。干燥及除水阶段可能伴随着熔融过程。
至今仍不知道生成的含过氧的硼化合物是否是过氧化氢与四硼酸盐或五硼酸盐的纯加合物。或含—B—O—O—H或—B—O—O—B—结构单元的化合物。甚至有可能含过氧的四或五硼酸盐在与生产相关的干燥过程中经历了部分的歧化过程,因此硼酸和从所谓的一水过硼酸钠中了解到的含结构单元的过硼酸盐可能在涂层中同时存在。
根据Ullmann’s Encyclopedia of Industrial Chemistry,5thEdition(1985),Vol.A4,270,用于形成上述含过氧的硼化合物的四硼酸盐和五硼酸盐具有以下阴离子结构:
Figure A9419173400081
四硼酸盐和五硼酸盐含有锂、钠或钾阳离子,优选钠阳离子。
优选的涂敷的过碳酸钠颗粒含通式为:Na2B4O7·nH2O2·mH2O的所谓的过四硼酸钠,其中n是1到4的整数,m是0到9的整数,做为涂层中的含过氧的硼化合物。优选每摩尔四硼酸盐结合2到4摩尔过氧化氢和0到2摩尔水。在特别优选的实施方案中,涂层基本上是Na2B4O7·4H2O2
除了依照本发明的含过氧的硼化合物,尤其是相应的通式为Na2B4O7·4H2O2的过四硼酸钠外,涂层还可以含有均匀分布的其它已知起稳定作用的涂敷组分,如前面提到的那些稳定剂。如果需要,本发明中涂层外还可以包敷有其它几层含除本发明中使用的含过氧的硼化合物之外的其它稳定剂的涂层,以及非必须地包敷有含通用洗涤剂和清洁剂组合物中各组分如沸石的涂层。另外的这些涂层可以通过标准方法,尤其是通过喷淋、混合及造粒过程涂敷到根据本发明涂敷的过碳酸钠颗粒上。
根据本发明涂敷的过碳酸钠颗粒的涂敷量范围很宽,尽管按过碳酸钠计,1~30wt%的涂层量都可行,但实际证明使用1~10wt%,优选2~6wt%的涂敷量更有利。一方面,这些限定量的涂敷物提供给过碳酸钠以足够的稳定性以抵抗在潮湿环境中在与通常的洗涤剂、清洁剂和漂白剂组合物混合贮存时活性氧的损失;另一方面,涂敷的过碳酸钠的硼含量保持在低水平。
正如已经提到的,根据本发明的过碳酸钠颗粒的单层或多层涂层中可以含有除过氧化氢与四硼酸酸或五硼酸盐反应的产物之外的其它涂敷组分。有利的是,整个涂层含大于50wt%,尤其是大于70wt%的前面提到的过氧化氢与四硼酸盐或五硼酸盐的反应产物和小于50wt%,尤其是小于30wt%的其它稳定化合物。根据本发明涂敷的具有单涂层的过碳酸钠颗粒,该涂层基本上是本发明中使用的含过氧的硼化合物,在洗涤剂塔粉(Tower Powder)存在时表现出非常高的贮存稳定性,这种稳定剂是仅使用标准的过硼酸盐所达不到的,尽管硼含量保持一样。这点令人十分惊奇,因为分子式为Na2B4O7·4H2O2的过四硼酸钠不如一水过硼酸钠这么稳定。
根据本发明涂敷的过硼酸钠颗粒可以用以下方法制备,将至少一种含过氧的硼化合物和,如果需要,其它涂敷组分、优选使用其水溶液,涂敷到基本上为过碳酸钠的颗粒上,以及如果需要,再干燥生成的湿颗粒。该方法的特征在于,一种或多种由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液得到的反应产物用做含过氧的硼化合物。
涂敷组分优选以其水溶液的形式涂敷到过碳酸钠颗粒上。从四硼酸盐或五硼酸盐与过氧化氢反应得到的反应混合物最好直接使用。
如果需要,含活性氧的硼化合物可以从反应混合物中回收,即将反应混合物溶液进一步浓缩或者甚至是部分或完全蒸发掉存在的水份使之成为固体,并且可以就这样用于本发明方法中。反应混合物最好照此方法直接制备以使含过氧的硼化合物保持所需的浓度。由于四硼酸盐或五硼酸盐与过氧化氢的反应产物其溶解度高,可以获得高浓度的含过氧的硼化合物溶液。这类溶液的好处在于,当它们通过喷淋嘴喷洒到过碳酸钠颗粒上时,不会产生喷嘴堵塞,因此不会出现故障。同时,在干燥过程中只需除去少量的水份。在制备这种反应混合物时,反应物的使用量要保证硼与活性氧的原子比为1∶0.2到1∶1.5。但优选硼与活性氧的原子比为1∶0.5到1∶1.25,尤其优选其原子比为1∶1或1:基本为1。在一特别优选的实施方案中,涂敷的过碳酸钠颗粒上的溶液含通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为1到4的整数,优选2到4,更优选约为4的整数。在使用含Na2B4O7·4H2O2的溶液的场合下,如果溶液中另含有少量过量过氧化氢,使硼原子与活性氧的原子比约为1∶1.05~1.15,则是有利的。通过搅拌将四硼酸钠加入到过氧化氢水溶液中,很容易就得到了这种溶液。用这种方法可制备含有例如20~50wt%,尤其是25~40wt%的分子式为Na2B4O7·nH2O2的过四硼酸钠溶液,其中n为2到4的整数,用于本发明的方法。
本发明方法中使用的含过氧的硼化合物可以使用标准方法一步或分几步以连续或间断的方式涂敷到主要成份为过碳酸钠的颗粒上。待涂颗粒可以是干燥的或含有生产过程中残留的水份的过碳酸钠。因此,甚至可以使用如离心含水的或部分干燥的过碳酸钠。根据本发明涂敷的过碳酸钠颗粒可以通过将表面含水的过碳酸钠与粉末状的过四硼酸钠混合来制备,如果需要,随后进行干燥。但更有利的是将涂层组分溶液涂敷到过碳酸钠颗粒上。合适的方法有:例如,将溶液喷淋到颗粒上,同时进行混合;合适的混合器有:例如喷淋混合器如转筒、滚桶混合器、盘式造粒机等。在上述实施方案的替换实施方案中,湿法生产的过碳酸钠用本发明中的含过氧的硼化合物水溶液处理,该过程在如固/液分离器的清洗装置中进行,除去过量的溶液后,所得产物进行干燥。该实施方案相当于迄今尚未出版的德国专利申请书P4306399·3中的实施方案,不同的是在较早的申请书的方法中,使用了含过硼酸钠(NaBO2·H2O2)的溶液。在本发明的一特别优选的实施方案中,将水溶液喷洒在流化床中处于流化状态的待涂颗粒上。被喷洒的溶液加湿的颗粒同时或随后被干燥。如果使用流化床装置,通入加热到干燥温度的流化空气,可以同时进行喷淋和干燥。
含有依照本发明使用的含过氧的硼化合物及非必须的其它涂敷组分的溶液在喷淋过程中的温度可以是室温或直到约60℃的温度。在使用浓度特别高的溶液的场合下,最好将其加热,优选加热至30~50℃。在使用的溶液是通过四硼酸盐或五硼酸盐与过氧化氢反应得到的场合下,该溶液即将使用前的温度受着溶解热与反应热的影响大约位于所述的范围内。代替从反应物制备该溶液,该溶液也可以通过用水溶解经验式为Na2B4O7·4H2O2的过四硼酸钠来制备,正如DE—PS 548432中描述的;室温下1升水中可溶解过四硼酸钠达1kg。
用喷淋法获得的的湿的涂敷的过碳酸钠在通常干燥过碳酸钠的条件下进行干燥。因此,干燥温度在30~90℃范围内,优选50~80℃,更优选50~70℃。干燥温度应理解为待干燥颗粒的温度。因此,在一特别优选的实施方案中,该过程在流化床干燥器中进行的场合下,流化床温度在上述温度范围内。因此进入流化床干燥塔的干燥空气的温度高于流化床温度。
根据本发明涂敷的过碳酸钠颗粒可以做洗涤剂、清洁剂和漂白剂组合物中的漂白组份。根据本发明涂敷的过碳酸钠颗粒的突出优点是,其中的过碳酸钠具有意想不到的高贮存稳定性,因此通常条件下在这些组合物的贮存期间,活性氧的损失十分缓慢。在涂敷物用量相当及起始Oa含量高的情况下,所述组合物中根据本发明涂敷的过碳酸钠的贮存稳定性超过已知的其它涂敷过碳酸钠的水平。
含有根据本发明涂敷的过碳酸钠的洗涤剂、清洁剂和漂白剂组合物中,1~99wt%为该涂敷过碳酸钠,剩余的(配平至100wt%)为该组合物中常用的其它组份。虽然洗涤剂中过碳酸钠含量一般不超过20wt%,但漂白剂和清洁剂组合物中的过碳酸钠含量可以高得多。
含有根据本发明的涂敷的过碳酸钠的洗涤剂、清洁剂和漂白剂组合物中除上述的活性氧化合物之外,还含有一般浓度的其它常用组份。所述的其它组份特别包括以下成份:1.阳离子型、阴离子型、非离子型或两性表面活性剂;2.无机和/或有机增洁剂,其主要功能是螯合或络合影响水硬度的金属离子,例如沸石、多磷酸盐、氨基多乙酸和氨基多膦酸和聚羟羧酸;3.碱和无机电解质,如链烷醇胺和硅酸盐、碳酸盐和硫酸盐;4.N—酰基化合物和O—酰基化合物类的漂白活性剂,如;四乙酰乙二胺;5.组合物可能含的其它组分是:过氧化物稳定剂(尤其是镁盐)、污垢再沉积抑制剂、光亮剂、消泡剂、酶、消毒剂、防腐蚀剂、香料、染料和PH值调节剂、1到5类中各化合物的特例可以在DE—OS3321082的14—30页上到找到。
本发明涂敷的过碳酸钠颗粒在单独贮存或与洗涤剂、清洁剂和漂白组合物混合贮存时都表现出惊人的活性氧稳定性。仅使用过碳酸钠百分之儿的涂敷物量就能获得这种惊人的稳定程度。虽然知道硼酸、硼酸盐和过硼酸钠作涂敷组分是十分有效的,但本发明中优选的含过氧硼的化合物的有效性超过上述已知的硼化合物的有效性。本发明方法的实施十分简单:由于本发明中使用的过四硼酸钠和其它含过氧的硼化合物的溶解度很高,一步即可得到有效的涂层。另外,也不存在喷嘴阻塞产生的故障。干燥的耗能也保持很低的水平。
本发明通过以下实施例来说明。实施例1
通过苏打与过氧化氢在水相中反应得到的活性氧(Oa)含量为14.2wt%的过碳酸钠在一混合器内用含有通式为Na2B4O7·4H2O2的过四硼酸钠的溶液涂敷:
该涂敷溶液用以下步骤制备:将100.2g四硼酸钠(Na2B4O7·10H2O)溶于115.4g 35wt%的过氧化氢水溶液中,并加以搅拌及自生缓慢加热。该溶液含41wt%的Na2B4O7·4H2O和2.2wt%的H2O2。溶液中硼与活性氧的原子比为1∶1.13。
在实验用犁式混合器内将183g上述溶液喷洒到1500g过碳酸钠上,湿产品在流化床干燥塔内60℃下进行干燥。
涂敷过碳酰钠的Oa含量为14.4wt%;硼含量为0.61wt%,数据由Na2B4O7·4H2O2的使用量并以涂敷的过碳酸钠为基础计算的。表中列出涂敷的过碳酸钠加入到工业用含沸石的洗涤剂塔粉(Persil Supra TP)(其中15wt%为涂敷的过碳酸钠,85wt%为塔粉)后,在潮湿环境中混合物在洗涤剂包中贮存时的Oa稳定性。实施例2
在流化床干燥塔中将含过四硼酸钠(Na2B4O7·4H2O2)的溶液喷涂到过碳酸钠(依照实施例1)上,同时进行干燥。
该溶液是将四硼酸钠溶于19.5wt%的H2O2溶液而制得。Na2B4O7·4H2O2含量为31.2wt%;硼与活性氧的原子比为1∶1。将该溶液在50℃流化床温度下(干燥气体的入口温度110℃)通过一双组份喷嘴喷涂到过碳酸盐上。喷涂量为每100g份重过碳酸钠使用5份重过四硼酸钠;涂敷的过碳酸钠中的Oa含量为14.2wt%。表中列出了添加到粉状洗涤剂中的过碳酸钠Oa稳定性(塔粉和混合比同实施例1)。实施例3
重复实施例2,但不同的是喷涂溶液含分子式为Na2B4O7·2H2O2的过四硼酸钠;其含量为28.7wt%;硼与活性氧的原子比为1∶1。
涂敷量为过碳酸钠量的5wt%。涂敷过碳酸钠中的Oa含量为14.0wt%。洗涤剂塔粉中Oa稳定性也列于表中(塔粉和混合比同实施例1)。实施例4
离心含水的过碳酸钠(通过在水相在氯化钠及六偏磷酸钠存在下苏打与过氧化氢反应并结晶而制得)在离心机中后处理,即除去母液后用过四硼酸钠溶液(Na2B4O7·4H2O2的33wt%)洗涤,随后在流化床干燥塔中干燥。Na2B4O7·4H2O2的涂敷量为过碳酸钠的2.5wt%。硼含量约为0.3wt%。涂敷过碳酸钠的Oa含量为14.2wt%。其贮存稳定性列于表中。比较实施例1
使用DE—PS 2800916中的方法(见该说明书的实施例A6)用5wt%的原硼酸涂敷过碳酸钠。该涂敷的过碳酸钠的Oa含量为13.4wt%;硼含量为涂敷的过碳酸钠的0.83wt%。在洗涤剂混合物中贮存时的稳定性数据列于表中。比较实施例2
在一混合器内(同实施例1)将四硼酸钠水溶液(浓度为35wt%)喷涂到过碳酸钠上,每100份重过碳酸钠喷涂四硼酸钠的数量为5份重。所得物随后在70℃下进行干燥。
Oa含量为13.5wt%;涂敷的过碳酸盐中硼含量为0.55wt%,数据由涂敷的四硼酸钠计算出,其中假设干燥过程中四硼酸钠转化成Na2B4O7·5H2O。比较实施例3
依照DE—PS 2810379,用过硼酸钠和水玻璃涂敷的过碳酸钠。涂敷量为6wt%的一水过硼酸钠和1wt%水玻璃。涂敷的过碳酸钠的Oa含量为14.3wt%;硼含量为0.62wt%(数据由涂敷的NaBO2·H2O2量计算出)。在洗涤剂组合物中的稳定性数据列于表中。
为了估价稳定性,上述实施例及比较实施例中涂敷的过碳酸钠与工业用无磷酸盐但含沸石的洗涤剂塔粉(Persil Supra TP)混合(混合比为15∶85)后贮存于密封的洗涤剂包装袋中(0.4l),置于恒温30℃、相对湿度为80%的气候试验箱中。贮存开始及贮存2、4和8周后,以一般方法对混合物中的活性氧进行了测定,测定结果列于表中。对于几乎相同的硼含量来说,依照本发明涂敷的过碳酸钠颗粒显示了比用硼酸、四硼酸钠或一水过硼酸盐涂敷的过碳酸钠颗粒有更高的贮存稳定性。
             表             贮存稳定性
实施例号 涂敷物量(wt%) 涂敷的过碳酸钠的堆积密度(克/升) 在洗涤剂组合物中过碳酸钠的绝对Oa含量(wt%) 8周后Oa剩余量(%)
  开始    2周   4周    8周
    1234比较实施例CE 1CE 2CE 3 Na2B4O7·4 H2O25%Na2B4O7·4 H2O25%Na2B4O7·2 H2O25%Na2B4O7·4 H2O22.5%B(OH)35%Na2B4O7·1O H2O5%NaBO2·H2O26%     1050970990920970960940     14.414.214.014.213.413.514.3     13.813.913.313.912.712.313.3     13.712.612.912.811.311.912.8     12.511.511.210.98.39.610.0     86.880.98076.761.97170

Claims (10)

1.包含一种核和一种涂层的、涂敷的过碳酸钠颗粒,其核基本上为过碳酸钠且其涂层含有至少一种含过氧的硼化合物,其特征在于,由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的一种或多种反应产物为该含过氧的硼化合物。
2.根据权利要求1的涂敷的过碳酸钠颗粒,其特征在于,涂层中的含过氧的硼化合物是通式为Na2B4O7·nH2O2·mH2O的过四硼酸钠,其中n为1到4,优选2到4的整数;m为0到9,优选0到2的整数。
3.根据权利要求1或2的、涂敷的过碳酸钠颗粒,其特征在于,涂层量为过碳酸钠的1~10wt%,优选2~6wt%。
4.根据权利要求1到3的、涂敷的过碳酸钠颗粒,其特征在于,涂层含大于50wt%、优选大干70wt%的过氧化氢与四硼酸盐或五硼酸盐的反应产物及小于50wt%、优选小于30wt%的其它起稳定作用的化合物。
5.一种生产包含一种核和一种涂层的、涂敷的过碳酸钠颗粒的方法,该颗粒的核基本上是过碳酸钠,涂层含有一种或多种涂敷组分,其中包含至少一种含过氧的硼化合物,该方法包括,将至少一种含过氧的硼化合物和,如果需要,其它涂敷组分、优选以其水溶液形式,涂敷到基本上为过碳酸钠的颗粒上,如果需要的话,干燥其湿颗粒,该法的特征在于,由四硼酸二碱金属盐或五硼酸碱金属盐与过氧化氢水溶液反应的一种或多种反应产物作为该含过氧的硼化合物。
6.根据权利要求5的方法,其特征在于,所述的反应产物以其水溶液形式使用,优选以反应混合物的水溶液形式使用,所述的溶液含有硼和活性氧,其硼与活性氧的原子比为1∶0.2到1∶1.5,优选1∶0.5到1∶1.25,更优选的为1:实质上的1。
7.根据权利要求5或6的方法,其特征在于,涂敷的溶液含通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为1到4的整数,优选2到4的整数。
8.根据权利要求5至7任一项的方法,其特征在于,涂敷的溶液含20~50wt%、尤其是25~40wt%通式为Na2B4O7·nH2O2的过四硼酸钠,其中n为2到4的整数,尤其是4。
9.根据权利要求5至8中任一项的方法,其特征在于,在一混合器或流化床干燥塔中将含过氧的硼化合物的水溶液喷涂到主要成份为过碳酸钠的颗粒上,得到的湿颗粒同时或随后在30~90℃、优选50~80℃下进行干燥。
10.含有根据权利要求1至3或根据权利要求4至9的方法制得的、涂敷的过碳酸钠颗粒的洗涤剂、清洁剂和漂白剂组合物。
CN94191734A 1993-04-10 1994-02-28 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物 Pending CN1120832A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4311944A DE4311944A1 (de) 1993-04-10 1993-04-10 Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
DEP4311944.1 1993-04-10

Publications (1)

Publication Number Publication Date
CN1120832A true CN1120832A (zh) 1996-04-17

Family

ID=6485306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94191734A Pending CN1120832A (zh) 1993-04-10 1994-02-28 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物

Country Status (17)

Country Link
US (1) US5658873A (zh)
EP (1) EP0693039B1 (zh)
JP (1) JP3599737B2 (zh)
KR (1) KR100308473B1 (zh)
CN (1) CN1120832A (zh)
AT (1) ATE156096T1 (zh)
AU (1) AU6207894A (zh)
CA (1) CA2159991A1 (zh)
CZ (1) CZ249895A3 (zh)
DE (2) DE4311944A1 (zh)
ES (1) ES2106515T3 (zh)
FI (1) FI954808A0 (zh)
PL (1) PL173925B1 (zh)
SI (1) SI9400166A (zh)
TR (1) TR27402A (zh)
TW (1) TW265320B (zh)
WO (1) WO1994024044A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101270232B (zh) * 2008-04-22 2011-04-20 浙江时代金科过氧化物有限公司 一种颗粒型包膜过碳酸钠的制备方法

Families Citing this family (550)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
DE4439069A1 (de) * 1994-11-02 1996-05-09 Degussa Percarbonathaltige Wasch-, Bleich- und Reinigungsmittelzusammensetzung
DE19629381A1 (de) * 1996-07-20 1998-01-22 Eilenburger Elektrolyse & Umwelttechnik Gmbh Granulierter Aktivsauerstoffträger
DE19544293C2 (de) * 1995-11-28 1998-01-29 Degussa Umhüllte Natriumpercarbonatpartikel und deren Verwendung
DE19600018A1 (de) 1996-01-03 1997-07-10 Henkel Kgaa Waschmittel mit bestimmten oxidierten Oligosacchariden
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
FR2768140B1 (fr) * 1997-09-05 1999-10-08 Atochem Elf Sa Solution sursaturee stable de perborate de sodium et son application dans la fabrication des particules de percarbonate de sodium stabilisees
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
CA2329130A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
JP2002515514A (ja) 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6225293B1 (en) 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
AU9576798A (en) * 1998-09-23 2000-04-10 Procter & Gamble Company, The Coated perborate bleach and compositions containing the same
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
EP1127840A1 (en) * 2000-02-21 2001-08-29 SOLVAY & Cie (Société Anonyme) Process for preparing coated alkali metal percarbonate, coated alkaki metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it
CA2406192A1 (en) * 2000-04-13 2001-10-25 Thomas N. Wight Therapeutic compounds and methods for formulating v3, a versican isoform
KR100366556B1 (ko) 2000-04-26 2003-01-09 동양화학공업주식회사 세제용 입상 코티드 과탄산나트륨과 이의 제조방법
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (en) 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
EP1377165B1 (en) 2001-03-14 2009-07-01 Myriad Genetics, Inc. Tsg101-gag interaction and use thereof
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
EP1404698A4 (en) 2001-06-21 2004-12-22 Isis Pharmaceuticals Inc ANTI-SENSE MODULATION OF SOLUBLE SUPEROXIDE DISMUTASE 1 EXPRESSION
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2002334895B2 (en) 2001-10-09 2006-10-19 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US7169916B2 (en) * 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) * 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EA008940B1 (ru) 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
WO2004027035A2 (en) * 2002-09-20 2004-04-01 Yale University Riboswitches, methods for their use, and compositions for use with riboswitches.
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044138A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
WO2004044132A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
ES2420914T3 (es) 2002-11-13 2013-08-27 Genzyme Corporation Modulación antisentido de la expresión de la apolipoproteína B
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
EP1572971B1 (en) 2002-11-15 2009-09-30 Morphotek Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
ES2392511T3 (es) 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
AU2003294462C1 (en) 2002-11-21 2011-06-30 University Of Utah Research Foundation Purinergic modulation of smell
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040121338A1 (en) * 2002-12-19 2004-06-24 Alsmadi Osama A. Real-time detection of rolling circle amplification products
WO2004058987A2 (en) 2002-12-20 2004-07-15 Qiagen Gmbh Nucleic acid amplification
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7002006B2 (en) * 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
CA2524495A1 (en) 2003-06-03 2005-01-13 Eli Lilly And Company Modulation of survivin expression
WO2005014782A2 (en) 2003-06-13 2005-02-17 Alnylam Europe Ag., Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2004113496A2 (en) 2003-06-20 2004-12-29 Isis Pharmaceuticals, Inc. Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
NZ576775A (en) 2003-09-18 2010-12-24 Isis Pharmaceuticals Inc Modulation of eIF4E expression
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1689432B1 (en) 2003-11-17 2009-12-30 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP2363480A3 (en) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1730309B1 (en) 2004-03-15 2016-05-04 Ionis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2005230684B2 (en) 2004-04-05 2011-10-06 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
NZ550772A (en) 2004-05-21 2009-10-30 Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1809303B1 (en) 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
ES2392449T3 (es) 2004-10-20 2012-12-10 Antisense Therapeutics Ltd Modulación antisentido de la expresión de la integrina alfa-4
US20060105937A1 (en) * 2004-11-15 2006-05-18 Melani Hardt Duran Aqueous cleaning composition
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
CA2597325A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP1863908B1 (de) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
GB0508622D0 (en) * 2005-04-28 2005-06-08 Probe Ind Ltd Method for treating effluent
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
EP1904111A4 (en) 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR DECREASING MICROARN EXPRESSION FOR THE TREATMENT OF NEOPLASIA
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007032837A2 (en) 2005-08-11 2007-03-22 The J. Craig Venter Institute Method for in vitro recombination
KR20080036646A (ko) 2005-08-17 2008-04-28 메덱시스 에스.에이. Ck19 발현 측정을 위한 조성물 및 방법
DE602006019455D1 (de) 2005-08-29 2011-02-17 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
EP1931780B1 (en) 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
AU2006304321B2 (en) 2005-10-14 2012-10-04 Musc Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2325315B1 (en) 2005-10-28 2014-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
EP1942948A4 (en) * 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
AU2006311730B2 (en) 2005-11-09 2010-12-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
AU2006318194B2 (en) 2005-11-21 2012-08-09 Isis Pharmaceuticals, Inc. Modulation of eiF4E-BP2 expression
WO2007100412A2 (en) * 2005-12-21 2007-09-07 Yale University Methods and compositions related to the modulation of riboswitches
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
PL3210633T3 (pl) 2006-01-26 2019-12-31 Ionis Pharmaceuticals, Inc. Kompozycje i ich zastosowania ukierunkowane na huntingtynę
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
JP2009535383A (ja) 2006-05-03 2009-10-01 バルティック テクロノジー デヴェロプメント,リミテッド 強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ, インコーポレーテッド Pcsk9の発現を調節するための化合物および方法
EP2505649A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
CA2651453C (en) * 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007137156A2 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
AU2007253677B2 (en) 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
CA2660052A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
US20100137440A1 (en) * 2006-09-11 2010-06-03 Yale University Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
US7947487B2 (en) 2006-10-05 2011-05-24 Massachusetts Institute Of Technology Multifunctional encoded particles for high-throughput analysis
DK2092065T4 (da) 2006-10-18 2019-10-21 Ionis Pharmaceuticals Inc Antisense-forbindelser
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8084437B2 (en) * 2006-11-27 2011-12-27 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
WO2008094370A2 (en) 2006-12-22 2008-08-07 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
MX2009008470A (es) 2007-02-09 2009-11-26 Univ Northwestern Particulas para detectar objetivos intracelulares.
EP2129803A4 (en) * 2007-02-27 2010-11-03 Univ Northwestern FIXING MOLECULES TO NANOPARTICLES
KR20100015757A (ko) 2007-03-22 2010-02-12 예일 유니버시티 택일적 스플라이싱을 조절하는 리보스위치와 관련된 방법 및 조성물
EP2905336A1 (en) 2007-03-29 2015-08-12 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of a gene from the ebola
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
CA2687684A1 (en) * 2007-05-29 2008-12-11 Yale University Methods and compositions related to riboswitches that control alternative splicing and rna processing
KR20100017905A (ko) * 2007-05-29 2010-02-16 예일 유니버시티 리보스위치, 리보스위치의 사용 방법 및 리보스위치를 함유하는 조성물
DK2826863T3 (en) 2007-05-30 2017-12-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7807372B2 (en) * 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) * 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
WO2009023855A2 (en) * 2007-08-15 2009-02-19 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
EP2682400B1 (en) 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009039466A1 (en) 2007-09-20 2009-03-26 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
EP2222851B1 (en) 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation of cd40 expression
WO2009076400A2 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
CA2709875C (en) 2008-01-02 2019-07-16 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
NZ588280A (en) 2008-03-05 2012-11-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2009124238A1 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2009124295A2 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
ES2554168T3 (es) 2008-04-18 2015-12-16 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
EP2280995A2 (en) * 2008-04-29 2011-02-09 Wyeth LLC Methods for treating inflammation
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
WO2010014592A1 (en) 2008-07-29 2010-02-04 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
ES2657696T3 (es) 2008-08-25 2018-03-06 Excaliard Pharmaceuticals, Inc. Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
KR101762734B1 (ko) 2008-08-25 2017-07-28 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
US8318693B2 (en) 2008-09-02 2012-11-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mutant EGFR gene
DK2356129T3 (da) * 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US20100075883A1 (en) * 2008-09-24 2010-03-25 Ecolab Inc. Granular cleaning and disinfecting composition
EP3584320A1 (en) 2008-09-25 2019-12-25 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
PL2350043T3 (pl) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
EA029762B1 (ru) 2008-10-20 2018-05-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
CA2744207C (en) 2008-11-24 2019-05-28 Northwestern University Polyvalent rna-nanoparticle compositions
CN102317458B (zh) 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
CN102307997B (zh) 2008-12-04 2018-03-30 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) * 2009-01-15 2015-08-25 삼성전자주식회사 전자 사진용 토너 및 그의 제조방법
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
EP2396408B1 (en) 2009-02-12 2017-09-20 CuRNA, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
US20110319317A1 (en) 2009-03-04 2011-12-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
CN102449170A (zh) 2009-04-15 2012-05-09 西北大学 寡核苷酸功能化的纳米颗粒的递送
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
EP2421972A2 (en) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
ES2661787T3 (es) 2009-05-01 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
JP5889783B2 (ja) 2009-05-05 2016-03-22 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation 免疫細胞へオリゴヌクレオチドを送達する方法
WO2010129709A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc. Lipid compositions
CA2761152A1 (en) 2009-05-06 2010-11-11 Opko Curna, Llc Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
WO2010132665A1 (en) 2009-05-15 2010-11-18 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
EP2435571B1 (en) 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
DK3449926T3 (da) 2009-06-17 2019-11-11 Biogen Ma Inc Sammensætninger og fremgangsmåder til modulering af smn2-splejsning hos et individ
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN102762731B (zh) 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en) 2009-08-17 2012-06-21 Yale University Methylation biomarkers and methods of use
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
CA2778532A1 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
US20110110860A1 (en) 2009-11-02 2011-05-12 The Board Of Regents Of The University Of Texas System Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
EP2496716A1 (en) 2009-11-03 2012-09-12 University Of Virginia Patent Foundation Versatile, visible method for detecting polymeric analytes
US8916362B2 (en) 2009-11-23 2014-12-23 Swift Biosciences, Inc. Devices comprising a polynucleotide to extend single stranded target molecules
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
CN102712927B (zh) 2009-12-16 2017-12-01 库尔纳公司 通过抑制膜结合转录因子肽酶,位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
CN102781480B (zh) 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CN102770540B (zh) 2009-12-29 2017-06-23 库尔纳公司 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
CN102906264B (zh) 2010-01-04 2017-08-04 库尔纳公司 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
JP6027893B2 (ja) 2010-01-11 2016-11-16 カッパーアールエヌエー,インコーポレイテッド 性ホルモン結合グロブリン(shbg)に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン(shbg)関連疾患の治療
WO2011088076A2 (en) 2010-01-12 2011-07-21 Yale University Structured rna motifs and compounds and methods for their use
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
NO2529015T3 (zh) 2010-01-25 2018-04-14
WO2011097388A1 (en) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Selective inhibition of polyglutamine protein expression
CA2824843A1 (en) 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US20130101512A1 (en) 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
JP5860029B2 (ja) 2010-03-29 2016-02-16 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
EP2555778A4 (en) 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (fgf21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (fgf21) 관련된 질환의 치료
US20110269194A1 (en) 2010-04-20 2011-11-03 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
CA2798218A1 (en) 2010-05-03 2011-11-10 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制par4天然反股轉錄本治療par4相關疾病
NO2576783T3 (zh) 2010-05-26 2018-04-28
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2576839B1 (en) 2010-06-07 2017-05-10 Firefly Bioworks, Inc. Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
WO2011156713A1 (en) 2010-06-11 2011-12-15 Vanderbilt University Multiplexed interferometric detection system and method
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
ES2663598T3 (es) 2010-07-14 2018-04-16 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo de discos grandes (dlg) mediante la inhibición del transcrito antisentido natural a dlg
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
DK2633052T3 (en) 2010-10-27 2018-07-16 Curna Inc TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
KR102010598B1 (ko) 2010-11-23 2019-08-13 큐알엔에이, 인크. Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
CA2825059A1 (en) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
RU2615117C2 (ru) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. ДВУХЦЕПОЧЕЧНАЯ МОЛЕКУЛА РНК ДЛЯ ОБЕСПЕЧЕНИЯ КЛЕТКИ АКТИВНОСТЬЮ miR-34a
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
CN118792301A (zh) 2011-03-29 2024-10-18 阿尔尼拉姆医药品有限公司 用于抑制tmprss6基因表达的组合物和方法
WO2012138453A1 (en) 2011-04-03 2012-10-11 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
KR102395085B1 (ko) 2011-06-21 2022-05-09 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
KR20230084331A (ko) 2011-06-21 2023-06-12 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP2723351B1 (en) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
EP3597750B1 (en) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP2742056B2 (en) 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
ES2856091T3 (es) 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
US9580713B2 (en) 2011-09-17 2017-02-28 Yale University Fluoride-responsive riboswitches, fluoride transporters, and methods of use
TW201321414A (zh) 2011-10-14 2013-06-01 Genentech Inc 抗-HtrA1抗體及其使用方法
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013106358A1 (en) 2012-01-10 2013-07-18 Hussain M Mahmood Method of treating hyperlipidemia and atherosclerosis with mir-30c
CN104395480B (zh) 2012-03-13 2018-01-30 斯威夫特生物科学公司 用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物
HUE040179T2 (hu) 2012-03-15 2019-02-28 Curna Inc Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
EP2839006B1 (en) 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
US20140038182A1 (en) 2012-07-17 2014-02-06 Dna Logix, Inc. Cooperative primers, probes, and applications thereof
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
EP2906699A4 (en) 2012-10-11 2016-06-08 Ionis Pharmaceuticals Inc OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
EP2912179A4 (en) 2012-10-26 2016-10-12 Geron Corp C-MYC ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
EP2961853B1 (en) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CA2904654C (en) 2013-03-14 2023-12-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
BR112015029276B1 (pt) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
HUE038146T2 (hu) 2013-05-22 2018-09-28 Alnylam Pharmaceuticals Inc Serpina1 IRNS készítmények és eljárások alkalmazásukra
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
ES2862125T3 (es) 2013-06-13 2021-10-07 Antisense Therapeutics Ltd Terapia combinada para acromegalia
EP3019619B1 (en) 2013-07-11 2021-08-25 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
PL3041854T3 (pl) 2013-08-08 2020-06-29 The Scripps Research Institute Sposób miejscowo specyficznego oznakowania enzymatycznego kwasów nukleinowych in vitro przez inkorporację niewystępujących naturalnie nukleotydów
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052626A1 (en) 2013-10-02 2016-08-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
UA124961C2 (uk) 2013-10-04 2021-12-22 Елнілем Фармасьютикалз, Інк. ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
WO2015054451A1 (en) 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
CA2932122C (en) 2013-12-03 2022-04-19 Northwestern University Liposomal particles, methods of making same and uses thereof
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
SG11201604692UA (en) 2013-12-12 2016-07-28 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
JP6599334B2 (ja) 2013-12-20 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
CN106103718B (zh) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
EP4162940A1 (en) 2014-04-17 2023-04-12 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療serpinc1相關疾患之方法和組成物
MX2016015126A (es) 2014-05-22 2017-02-23 Alnylam Pharmaceuticals Inc Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
CA2950589A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US9951327B1 (en) 2014-07-17 2018-04-24 Integrated Dna Technologies, Inc. Efficient and rapid method for assembling and cloning double-stranded DNA fragments
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
JP6797108B2 (ja) 2014-08-19 2020-12-09 ノースウェスタン ユニバーシティ タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP4043567B1 (en) 2014-08-29 2024-05-08 The Children's Medical Center Corporation Methods and compositions for the treatment of cancer
KR102631505B1 (ko) 2014-08-29 2024-02-01 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
AU2015318782A1 (en) 2014-09-18 2017-04-06 The University Of British Columbia Allele-specific therapy for Huntington Disease haplotypes
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
AU2015344741A1 (en) 2014-11-10 2017-05-25 Glaxosmithkline Intellectual Property (No.2) Limited Combination long acting compositions and methods for hepatitis C
WO2016075583A1 (en) 2014-11-10 2016-05-19 Glaxosmithkline Intelle Ctual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US20160145547A1 (en) 2014-11-25 2016-05-26 Milliken & Company Film-Encased Cleaning Composition
EP3234141A4 (en) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
EP3247988A4 (en) 2015-01-23 2018-12-19 Vanderbilt University A robust interferometer and methods of using same
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
MX2017012407A (es) 2015-03-27 2018-03-07 Harvard College Celulas t modificadas y métodos para hacer y usar las mismas.
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
AU2016295168B2 (en) 2015-07-17 2021-08-19 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3332009A1 (en) 2015-08-04 2018-06-13 Yeda Research and Development Co., Ltd. Methods of screening for riboswitches and attenuators
AU2016315584B2 (en) 2015-09-02 2022-07-14 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
CA3001362C (en) 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
EP3370734B1 (en) 2015-11-05 2023-01-04 Children's Hospital Los Angeles Antisense oligo for use in treating acute myeloid leukemia
CA3007152A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
RU2754188C2 (ru) 2015-12-07 2021-08-30 Джензим Корпорейшн Способы и композиции для лечения ассоциированного с serpinc1 расстройства
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
EP3408649B1 (en) 2016-01-29 2023-06-14 Vanderbilt University Free-solution response function interferometry
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. 補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
DK3475295T3 (da) 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
KR20230088522A (ko) 2016-07-21 2023-06-19 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
WO2018183969A1 (en) 2017-03-30 2018-10-04 California Institute Of Technology Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
CN110913898B (zh) 2017-04-18 2024-04-05 阿尔尼拉姆医药品有限公司 具有乙肝病毒(hbv)感染的受试者的治疗方法
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
AU2018301477A1 (en) 2017-07-13 2020-02-27 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
CA3071013A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019055460A1 (en) 2017-09-13 2019-03-21 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
JP2021508333A (ja) 2017-09-19 2021-03-04 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. トランスサイレチン(ttr)媒介アミロイドーシスの治療用組成物及び方法
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2019099610A1 (en) 2017-11-16 2019-05-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
KR20200110655A (ko) 2017-12-18 2020-09-24 알닐람 파마슈티칼스 인코포레이티드 고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
MX2020008772A (es) 2018-02-26 2020-10-01 Synthorx Inc Conjugados de il-15, y sus usos.
KR20200141470A (ko) 2018-04-06 2020-12-18 칠드런'즈 메디컬 센터 코포레이션 체세포 재프로그래밍 및 각인의 조정을 위한 조성물 및 방법
JP7353301B2 (ja) 2018-05-07 2023-09-29 アルニラム ファーマスーティカルズ インコーポレイテッド 肝臓外送達
CN118685406A (zh) 2018-05-14 2024-09-24 阿尔尼拉姆医药品有限公司 血管紧张素原(AGT)iRNA组合物及其使用方法
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
TW202020157A (zh) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 用於抑制lect2基因表現之組合物及方法
WO2020056341A2 (en) 2018-09-14 2020-03-19 Northwestern University Programming protein polymerization with dna
US20210332367A1 (en) 2018-09-18 2021-10-28 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202028465A (zh) 2018-09-28 2020-08-01 美商阿尼拉製藥公司 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
US20210332495A1 (en) 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
WO2020132521A1 (en) 2018-12-20 2020-06-25 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
US20220056110A1 (en) 2018-12-20 2022-02-24 Vir Biotechnology, Inc. Combination hbv therapy
MX2021008628A (es) 2019-01-16 2021-11-17 Genzyme Corp Composiciones de arni para serpinc1 y metodos de uso de las mismas.
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
WO2020191177A1 (en) 2019-03-21 2020-09-24 Sudhir Agrawal Antisense oligonucleotides for allele specificity
MX2021013698A (es) 2019-05-13 2021-12-10 Vir Biotechnology Inc Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb).
WO2020236600A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2020252262A1 (en) 2019-06-14 2020-12-17 The Scripps Research Institute Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
WO2021030522A1 (en) 2019-08-13 2021-02-18 Alnylam Pharmaceuticals, Inc. SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2022001776A (es) 2019-08-15 2022-03-17 Synthorx Inc Terapias de combinacion de inmuno oncologia con conjugados de il-2.
US20210054040A1 (en) 2019-08-23 2021-02-25 Synthorx, Inc. Novel il-15 conjugates and uses thereof
US20220290152A1 (en) 2019-09-03 2022-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CA3150082A1 (en) 2019-09-10 2021-03-18 Jerod PTACIN IL-2 CONJUGATES AND METHODS OF USE FOR TREATING AUTOIMMUNE DISEASES
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en) 2019-10-18 2021-04-22 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
MX2022004726A (es) 2019-10-22 2022-05-13 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de componente c3 de complemento y metodos de uso de las mismas.
TW202132567A (zh) 2019-11-01 2021-09-01 美商阿尼拉製藥公司 亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
EP4051796A1 (en) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
WO2021091986A1 (en) 2019-11-04 2021-05-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
KR20220110749A (ko) 2019-11-06 2022-08-09 알닐람 파마슈티칼스 인코포레이티드 간외 전달
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
EP4061945A1 (en) 2019-11-22 2022-09-28 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
KR20220115995A (ko) 2019-12-13 2022-08-19 알닐람 파마슈티칼스 인코포레이티드 인간 염색체 9 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
JP2023514190A (ja) 2020-02-10 2023-04-05 アルナイラム ファーマシューティカルズ, インコーポレイテッド Vegf-a発現をサイレンシングするための組成物および方法
IL295496A (en) 2020-02-18 2022-10-01 Alnylam Pharmaceuticals Inc Apolipoprotein c3 (apoc3) irna preparations and methods of using them
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
CN115485383A (zh) 2020-03-06 2022-12-16 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
EP4127168A1 (en) 2020-03-26 2023-02-08 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
EP4127171A2 (en) 2020-03-30 2023-02-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
WO2021207167A1 (en) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
EP4133077A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN116134135A (zh) 2020-04-07 2023-05-16 阿尔尼拉姆医药品有限公司 用于沉默scn9a表达的组合物和方法
MX2022013525A (es) 2020-04-27 2023-01-24 Alnylam Pharmaceuticals Inc Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
EP4142738A1 (en) 2020-04-30 2023-03-08 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
CA3162416C (en) 2020-05-15 2023-07-04 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150087A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150086A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4153746A1 (en) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (es) 2020-06-03 2022-09-21 Triplet Therapeutics Inc Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
AU2021292296A1 (en) 2020-06-18 2023-01-19 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
TW202208422A (zh) 2020-06-24 2022-03-01 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
IL299074A (en) 2020-06-25 2023-02-01 Synthorx Inc Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
EP4217489A1 (en) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
JP2023546009A (ja) 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Il-2コンジュゲートおよびペムブロリズマブを用いる免疫腫瘍学併用療法
KR20230084204A (ko) 2020-10-09 2023-06-12 신톡스, 인크. Il-2 콘쥬게이트를 사용한 면역 종양학 치료법
WO2022087041A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
WO2022103999A1 (en) 2020-11-13 2022-05-19 Alnylam Pharmaceuticals, Inc. COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022119873A1 (en) 2020-12-01 2022-06-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
US20240175020A1 (en) 2020-12-23 2024-05-30 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
US20240336914A1 (en) 2020-12-31 2024-10-10 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
JP2024501857A (ja) 2020-12-31 2024-01-16 アルナイラム ファーマシューティカルズ, インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
TW202302148A (zh) 2021-02-12 2023-01-16 美商欣爍克斯公司 使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
WO2022174101A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Skin cancer combination therapy with il-2 conjugates and cemiplimab
AU2022220704A1 (en) 2021-02-12 2022-08-18 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
CN117222739A (zh) 2021-02-25 2023-12-12 阿尔尼拉姆医药品有限公司 朊病毒蛋白(prnp)irna组合物和其使用方法
CA3211059A1 (en) 2021-02-26 2022-09-01 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
IL305442A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
US20220288181A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
JP2024519601A (ja) 2021-03-31 2024-05-20 エントラーダ セラピューティクス,インコーポレイティド 環状細胞透過性ペプチド
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
WO2022212153A1 (en) 2021-04-01 2022-10-06 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
WO2022232343A1 (en) 2021-04-29 2022-11-03 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
JP2024518374A (ja) 2021-05-03 2024-05-01 アルナイラム ファーマシューティカルズ, インコーポレイテッド トランスサイレチン(ttr)媒介性アミロイドーシスを治療するための組成物および方法
EP4337263A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
JP2024518476A (ja) 2021-05-10 2024-05-01 エントラーダ セラピューティクス,インコーポレイティド mRNAスプライシングを調節するための組成物及び方法
JP2024522068A (ja) 2021-05-18 2024-06-11 アルナイラム ファーマシューティカルズ, インコーポレイテッド ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
WO2022246023A1 (en) 2021-05-20 2022-11-24 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
EP4347823A1 (en) 2021-06-02 2024-04-10 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202313117A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
AU2022283796A1 (en) 2021-06-04 2023-11-09 Alnylam Pharmaceuticals, Inc. HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
WO2022271818A1 (en) 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
EP4367237A2 (en) 2021-07-09 2024-05-15 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
EP4373934A1 (en) 2021-07-19 2024-05-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
WO2023003922A1 (en) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Metabolic disorder-associated target gene irna compositions and methods of use thereof
EP4373933A1 (en) 2021-07-23 2024-05-29 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (ja) 2021-07-29 2024-08-06 アルナイラム ファーマシューティカルズ, インコーポレイテッド 3-ヒドロキシ-3-メチルグリタル-COAレダクターゼ(HMGCR)iRNA組成物およびその使用方法
MX2024001194A (es) 2021-08-03 2024-02-27 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
WO2023014765A1 (en) 2021-08-04 2023-02-09 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
WO2023019246A1 (en) 2021-08-13 2023-02-16 Alnylam Pharmaceuticals, Inc. Factor xii (f12) irna compositions and methods of use thereof
MX2024002640A (es) 2021-09-01 2024-07-19 Entrada Therapeutics Inc Compuestos y metodos para salto de exon 44 en la distrofia muscular de duchenne.
EP4401742A2 (en) 2021-09-17 2024-07-24 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CA3233755A1 (en) 2021-10-01 2023-04-06 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
CA3234835A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
IL312399A (en) 2021-10-29 2024-06-01 Alnylam Pharmaceuticals Inc Complement factor B (CFB) iRNA compositions and methods of using them
TW202334418A (zh) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 杭丁頓(HTT)iRNA劑組成物及其使用方法
EP4433098A1 (en) 2021-11-18 2024-09-25 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
WO2024196937A1 (en) 2023-03-20 2024-09-26 Synthorx, Inc. Cancer therapy with il-2 peg conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE548432C (de) * 1928-10-17 1932-04-12 Degussa Herstellung eines Perborates
US1978953A (en) * 1928-10-17 1934-10-30 Du Pont Method of preparing an alkali metal perborate
US3327684A (en) * 1963-03-11 1967-06-27 Fairchild Camera Instr Co Masking apparatus for spray coating
FR2226460B1 (zh) * 1973-04-20 1976-12-17 Interox
JPS5315717B2 (zh) * 1973-12-20 1978-05-26
DE2652776A1 (de) * 1975-05-13 1978-05-24 Interox Chemicals Ltd Verfahren zur herstellung von natriumpercarbonat
LU72575A1 (zh) * 1975-05-23 1977-02-10
DE2651442C3 (de) * 1976-11-11 1979-11-15 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Natriumpercarbonat-Partikel
US4156039A (en) * 1976-11-11 1979-05-22 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler Sodium percarbonate particles (A)
DE2810379C3 (de) * 1978-03-10 1980-12-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von stabilisiertem Natriumpercarbonat
DE2712139C3 (de) * 1977-03-19 1982-05-19 Degussa Ag, 6000 Frankfurt Natriumpercarbonat-Schichtpartikel
LU76548A1 (zh) * 1977-01-10 1978-09-18
DE2800760C2 (de) * 1978-01-09 1983-01-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von Natriumpercarbonat aus einer Sodalösung bzw. -suspension
GB1575792A (en) * 1978-01-10 1980-10-01 Interox Peroxygen compounds
ES8503626A1 (es) * 1982-06-10 1985-03-01 Kao Corp Un procedimiento para la preparacion de percarborato sodico recubierto con un borato.
DE3321082C2 (de) * 1982-06-10 1996-08-22 Kao Corp Bleich-Reinigungsmittel
EP0117578A3 (en) * 1983-02-23 1985-01-30 Shionogi & Co., Ltd. Azole-substituted alcohol derivatives
DE3784787T2 (de) * 1986-06-23 1994-01-20 Du Pont Merck Pharma Fungizide Karbinole.
US4952232A (en) * 1987-04-29 1990-08-28 E. I. Du Pont De Nemours And Company Antifungal carbinols
DE3720277A1 (de) * 1987-06-19 1988-12-29 Degussa Verfahren zur verminderung der neigung zum zusammenbacken von teilchenfoermigen aktivsauerstoffverbindungen
DE3813874A1 (de) * 1987-07-10 1989-01-19 Bayer Ag Hydroxyalkyl-azolyl-derivate
DE3921481A1 (de) * 1989-06-30 1991-01-03 Bayer Ag Hydroxyethyl-cyclopropyl-azolyl-derivate
AU7184891A (en) * 1990-02-13 1991-09-03 E.I. Du Pont De Nemours And Company Aniline derivatives of alpha-styryl carbinols as antifungal agents
JP2636496B2 (ja) * 1990-11-21 1997-07-30 花王 株式会社 安定な過炭酸ソーダ粒子及びその製造法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101270232B (zh) * 2008-04-22 2011-04-20 浙江时代金科过氧化物有限公司 一种颗粒型包膜过碳酸钠的制备方法

Also Published As

Publication number Publication date
KR100308473B1 (ko) 2002-07-02
CZ249895A3 (en) 1996-04-17
US5658873A (en) 1997-08-19
AU6207894A (en) 1994-11-08
CA2159991A1 (en) 1994-10-27
KR960701801A (ko) 1996-03-28
FI954808A (fi) 1995-10-09
FI954808A0 (fi) 1995-10-09
ATE156096T1 (de) 1997-08-15
SI9400166A (en) 1994-12-31
PL311035A1 (en) 1996-01-22
EP0693039A1 (de) 1996-01-24
DE4311944A1 (de) 1994-10-13
ES2106515T3 (es) 1997-11-01
DE59403562D1 (de) 1997-09-04
JP3599737B2 (ja) 2004-12-08
TW265320B (zh) 1995-12-11
JPH08508707A (ja) 1996-09-17
TR27402A (tr) 1995-02-28
PL173925B1 (pl) 1998-05-29
WO1994024044A1 (de) 1994-10-27
EP0693039B1 (de) 1997-07-30

Similar Documents

Publication Publication Date Title
CN1120832A (zh) 涂敷过碳酸钠颗粒及其生产方法和含此颗粒的洗涤剂、清洁剂及漂白剂组合物
US3951838A (en) Silica sol stabilizers for improving the stability of sodium percarbonate in solid bleaches and detergents
US3977988A (en) Stabilized sodium percarbonate and process for preparing same
KR101434347B1 (ko) 코팅된 과탄산나트륨 입자
KR100885831B1 (ko) 티오술페이트 함유 쉘층을 갖는 과탄산나트륨 입자
CA2108513C (en) Sodium percarbonate stabilized by coating
US20060014658A1 (en) Sodium percarbonate particles with improved storage stability
PL186136B1 (pl) Kompozycja detergentowa zawierająca nadwęglan sodu
RU2136584C1 (ru) Способ стабилизации частиц перкарбоната щелочного металла
EP0675851B1 (en) Process for stabilising alkali percarbonate particles, particles obtained thereby and washing and/or bleaching compositions containing them
CN1056586C (zh) 加以包覆的碱金属过酸盐及其制备方法
KR20090035546A (ko) 코팅된 과탄산나트륨 입자
JPH07509268A (ja) 洗剤組成物
CN1054353C (zh) 稳定粒状碱金属过碳酸盐的方法
JPH0437119B2 (zh)
JPH0640709A (ja) 安定な過炭酸ソーダ及びその製造法並びに安定な過炭酸ソーダを含有する漂白洗浄剤組成物
JP2869310B2 (ja) 安定な過炭酸ソーダ及びその製造方法並びに安定な過炭酸ソーダを含有してなる漂白洗浄剤組成物
US20010048911A1 (en) Process for preparing a stabilized sodium carbonate peroxyhydrate
EP0675852B1 (en) Method for stabilising alkali percarbonate particles, particles obtained thereby and washing and/or bleaching compositions containing them
JPH0352795B2 (zh)
WO1995005341A2 (en) Oxidising bleach
US5744055A (en) Stable monopersulfate triple salt and its method of preparation
CN103068726A (zh) 包覆的过碳酸钠颗粒,其制备方法,其在洗涤剂组合物中的用途和含有它们的洗涤剂组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication